A randomized, double-blind, parallel-group, multicenter study to compare the glycemic effects, safety, and tolerability of exenatide long-acting release (once weekly) to those of sitagliptin and a thiazolidinedione in subjects with type 2 diabetes mellitus treated with metformin.

Trial Profile

A randomized, double-blind, parallel-group, multicenter study to compare the glycemic effects, safety, and tolerability of exenatide long-acting release (once weekly) to those of sitagliptin and a thiazolidinedione in subjects with type 2 diabetes mellitus treated with metformin.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Exenatide (Primary) ; Pioglitazone; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms DURATION-2
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Jun 2011 Pooled efficacy analysis results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
    • 17 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top